Compared side by side
Semaglutide vs efinopegdutide: how they differ
The short answer
Semaglutide acts on one receptor, GLP-1; efinopegdutide is a weekly GLP-1 and glucagon dual agonist that Merck is developing for MASH, the inflamed form of fatty liver disease, because glucagon acts on the liver directly. In a 24-week trial, efinopegdutide cut liver fat by about 73%, against 42% on semaglutide 1 mg. Semaglutide is FDA-approved for type 2 diabetes, weight management and MASH, as Ozempic and Wegovy; efinopegdutide isn’t approved anywhere.
Side by side
| Compared | Semaglutide | Efinopegdutide |
|---|---|---|
| Category | Metabolic & GLP-1 | Metabolic & GLP-1 |
| Also known as | Ozempic, Wegovy | MK-6024, JNJ-64565111, Efino |
| What it is | A GLP-1 receptor agonist that mimics a gut hormone your body releases after eating: it reduces appetite and slows stomach emptying. | A once-weekly GLP-1 and glucagon dual agonist that Merck is developing for MASH, the inflamed form of fatty liver disease. |
| How it works | GLP-1 receptor agonist that reduces appetite, slows gastric emptying, and improves glucose metabolism. FDA-approved for T2DM and obesity. Titrate dose slowly to minimize GI side effects. | Once-weekly GLP-1 and glucagon receptor co-agonist, the same pair as mazdutide and survodutide, tuned about 2 to 1 toward GLP-1. GLP-1 lowers appetite and weight; glucagon acts on the liver directly and is thought to make it burn more of its stored fat. That is why Merck is developing it for MASH, the inflamed form of fatty liver disease, rather than for weight alone. Investigational; first made by Hanmi Pharmaceutical, then tested by Janssen in obesity, and now with Merck. |
| Commonly reported | The constant background thoughts about food ("food noise") go quiet and portions shrink without effort, with nausea worst in the first days after each dose step. FDA-approved for type 2 diabetes, weight management, heart-risk reduction and MASH, with about 15% average weight loss at 68 weeks in its main trial. | GI side effects during step-ups, and weight loss too. Not approved anywhere. |
| Studied range | FDA label: 0.25–2.4 mg, starting dose 0.25 mg. | Research range: 4–10 mg, starting dose 2 mg. Studied in research — not a recommendation. |
| How often | Weekly SubQ | Weekly |
| Half-life | ~1 week (FDA label) | Not reported in an open human PK source; dosed once weekly in all its trials |
| Route | SubQ injection | SubQ injection |
| Typical run | FDA-approved for ongoing use. Community uses indefinitely or until goal weight reached, then tapers. | Used continuously, once weekly, in its trials: 24 to 52 weeks, stepping up every 4 weeks from 2 mg in the MASH trial. No trial has tested stopping it. |
| Evidence | Established: clinical trials or FDA-approved use exists | Moderate: animal studies + some human data |
| Common side effects | Nausea, vomiting, diarrhea, constipation, decreased appetite, fatigue, pancreatitis risk | Nausea, vomiting, diarrhea |
- Category
- SemaglutideMetabolic & GLP-1
- EfinopegdutideMetabolic & GLP-1
- Also known as
- SemaglutideOzempic, Wegovy
- EfinopegdutideMK-6024, JNJ-64565111, Efino
- What it is
- SemaglutideA GLP-1 receptor agonist that mimics a gut hormone your body releases after eating: it reduces appetite and slows stomach emptying.
- EfinopegdutideA once-weekly GLP-1 and glucagon dual agonist that Merck is developing for MASH, the inflamed form of fatty liver disease.
- How it works
- SemaglutideGLP-1 receptor agonist that reduces appetite, slows gastric emptying, and improves glucose metabolism. FDA-approved for T2DM and obesity. Titrate dose slowly to minimize GI side effects.
- EfinopegdutideOnce-weekly GLP-1 and glucagon receptor co-agonist, the same pair as mazdutide and survodutide, tuned about 2 to 1 toward GLP-1. GLP-1 lowers appetite and weight; glucagon acts on the liver directly and is thought to make it burn more of its stored fat. That is why Merck is developing it for MASH, the inflamed form of fatty liver disease, rather than for weight alone. Investigational; first made by Hanmi Pharmaceutical, then tested by Janssen in obesity, and now with Merck.
- Commonly reported
- SemaglutideThe constant background thoughts about food ("food noise") go quiet and portions shrink without effort, with nausea worst in the first days after each dose step. FDA-approved for type 2 diabetes, weight management, heart-risk reduction and MASH, with about 15% average weight loss at 68 weeks in its main trial.
- EfinopegdutideGI side effects during step-ups, and weight loss too. Not approved anywhere.
- Studied range
- SemaglutideFDA label: 0.25–2.4 mg, starting dose 0.25 mg.
- EfinopegdutideResearch range: 4–10 mg, starting dose 2 mg. Studied in research — not a recommendation.
- How often
- SemaglutideWeekly SubQ
- EfinopegdutideWeekly
- Half-life
- Semaglutide~1 week (FDA label)
- EfinopegdutideNot reported in an open human PK source; dosed once weekly in all its trials
- Route
- SemaglutideSubQ injection
- EfinopegdutideSubQ injection
- Typical run
- SemaglutideFDA-approved for ongoing use. Community uses indefinitely or until goal weight reached, then tapers.
- EfinopegdutideUsed continuously, once weekly, in its trials: 24 to 52 weeks, stepping up every 4 weeks from 2 mg in the MASH trial. No trial has tested stopping it.
- Evidence
- SemaglutideEstablished: clinical trials or FDA-approved use exists
- EfinopegdutideModerate: animal studies + some human data
- Common side effects
- SemaglutideNausea, vomiting, diarrhea, constipation, decreased appetite, fatigue, pancreatitis risk
- EfinopegdutideNausea, vomiting, diarrhea
Typical run: Community practice — opinions vary. Not a clinical recommendation.

Model. Individual results vary.
Week by week
Each entry’s cards by day window, as the compound pages show them. Day 1 is the day you start it.
Semaglutide
- Day 1–28 · 0.25 mg Gut is adapting
- Day 29–56 · 0.5 mg Appetite shifts are real now
- Day 57–112 · 1 mg Clinically useful weight loss kicks in
- Day 113–140 · 1.7 mg Max submaximal step
- Day 141–364 · 2.4 mg Full dose — the working dose
- Day 365+ Plateau territory — new baseline
Efinopegdutide
- Day 1–28 · 2 mg A gentle first month
- Day 29–364 · 4 mg Four milligrams
- Day 57–364 · 7 mg The dose the trial favoured
- Day 57–364 Weight comes down too
- Day 85–364 · 10 mg Ten milligrams: more side effects, not more benefit
Questions people ask
How long do semaglutide and efinopegdutide last?
The half-life of semaglutide is ~1 week (FDA label). The half-life of efinopegdutide is not reported in an open human PK source; dosed once weekly in all its trials.
How often are semaglutide and efinopegdutide taken?
Semaglutide: weekly SubQ. Route: SubQ injection. Efinopegdutide: weekly. Route: SubQ injection.
How are semaglutide and efinopegdutide dosed in research?
The FDA label range for semaglutide is 0.25–2.4 mg, with a 0.25 mg starting dose. The research range for efinopegdutide is 4–10 mg, with a 2 mg starting dose. Studied in research — not a recommendation.
What are the common side effects of semaglutide and efinopegdutide?
For semaglutide, the library lists: nausea, vomiting, diarrhea, constipation, decreased appetite, fatigue, pancreatitis risk. For efinopegdutide: nausea, vomiting, diarrhea.